Could the pharmaceutical giant turn things around next year? Let's find out whether Bristol Myers Squibb is a buy, sell, or ...

Bristol Myers Squibb (BMY) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to ...

Bristol-Myers Squibb Company (NYSE:BMY) is included among the 14 Best Pharma Dividend Stocks to Buy in 2026. On December 15, ...

Bristol Myers Squibb (BMY) is undervalued and poised for growth, with strong dividends and robust financials. Read here for ...

Amgen, Bristol Myers Squibb, Boehringer Ingelheim, Genentech, Gilead Sciences, GSK, Merck, Novartis and Sanofi will sell ...

COBENFY™ (xanomeline and trospium chloride) is a prescription medicine used to treat schizophrenia in adults. It is not known ...

With that, here are two dividend stocks to consider scooping up right now.

According to Benzinga Pro, Bristol-Myers Squibb Co's peer group average for short interest as a percentage of float is 3.35%, which means the company has less short interest than most of its peers.

Bristol-Myers Squibb Company is rated a Buy with solid rebound and robust free cash flow margins. Learn more about BMY stock ...

Bristol Myers Squibb Bristol Myers Squibb (NYSE: BMY) recently reported its Q1 results, with revenues and earnings above the street estimates. The company reported revenue of $11.9 billion and an ...

Bristol Myers Squibb (NYSE: BMY) is a big name in healthcare. And over the years, it has always found ways to grow and expand its business. But this hasn't been a good buy of late. It's not just this ...

The GLP-1 fight just entered a new round, and it highlights why these three out-of-favor drug makers are worth a deep dive.